首页> 外文期刊>Journal of Endocrinological Investigation: Official Journal of the Italian Society of Endocrinology >Long-term monitoring of rec-GH treatment by serial determination of serum aminoterminal propeptide of type III procollagen in children and adults with GH deficiency.
【24h】

Long-term monitoring of rec-GH treatment by serial determination of serum aminoterminal propeptide of type III procollagen in children and adults with GH deficiency.

机译:通过连续测定患有GH缺乏症的儿童和成人的III型胶原蛋白原的血清氨基末端前肽来长期监测rec-GH治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

Serum aminoterminal propeptide of type III procollagen (PIIINP) levels, a reliable marker of collagen formation, were evaluated in children (C=7) and adults with childhood-onset (CO=10) and acquired (A=18) GH deficiency (GHD) before, during and after withdrawal of rec-GH therapy (C=0.6 IU/kg/week, CO=0.5 IU/kg/week, A=0.25 IU/kg/week). The duration of treatment was 12 months for C and A and 6 months for CO; investigations were carried out before and at 3, 6, 9 and 12 months (for C and A) and at 3 and 6 months (for CO) of GH treatment and 6 months after the withdrawal of therapy (for A and CO). Data obtained from patients were compared with those recorded in two age- and sex-matched control groups. Before treatment, serum PIIINP levels were significantly lower (p<0.001) in C with GHD (mean+/-SE: 2.9+/-0.4 ng/ml) than in controls (6.1+/-0.4 ng/ml), while no significant differences were recorded between adults with CO/A-GHD (3.7+/-0.5 ng/ml and 3.4+/-0.2 ng/ml) and controls (3.2+/-0.2 ng/ml). GH treatment caused a significant increase (p<0.0001) of PIIINP levels both in C (3rd month: 4.4+/-0.2 ng/ml, 6th month: 5.1+/-0.4 ng/ml, 12th month: 5.1+/-0.5 ng/ml), CO-GHD (3rd month: 12.7+/-1.2 ng/ml; 6th month: 10.2+/-0.6 ng/ml) and A-GHD (3rd month: 10.0+/-1.0 ng/ml; 6th month: 8.4+/-0.6 ng/ml; 12th month: 7.0+/-0.7 ng/ml), the increase being dose-dependent (more marked and sustained in adults with CO-GHD). The maximal stimulation of collagen synthesis occurred after 3 months of GH treatment in adults with GHD, while a more gradual and less relevant increase was observed in C with GHD. Six months after the withdrawal of GH therapy, serum PIIINP levels of adults with CO-GHD (3.6+/-0.3 ng/ml) were similar to those recorded before treatment, while in adults with A-GHD serum PIIINP levels (2.6+/-0.2 ng/ml) were significantly lower (p<0.01) than in basal condition. In conclusion, our study shows that: a) GHD is associated with a reduction of soft tissue formation in children, while it seems to exert no relevant effects in adults with GHD; b) GH therapy causes a rapid stimulation of collagen turnover, which shows a different pattern in children and adults; c) the GH-induced stimulation of collagen synthesis is rapidly removed after the withdrawal of GH treatment. For these reasons, the determination of peripheral markers of GH effects appears useful for the monitoring of GH therapy and can contribute to assess the "tailored" substitutive dose for the individual patient.
机译:在儿童(C = 7)和儿童期成人(CO = 10)和获得性(A = 18)GH缺乏(GHD)的儿童(C = 7)和成年人中评估了III型胶原蛋白(III型胶原蛋白)的可靠标志物血清氨基末端前肽)在停用rec-GH治疗之前,期间和之后(C = 0.6 IU / kg /周,CO = 0.5 IU / kg /周,A = 0.25 IU / kg /周)。 C和A的治疗时间为12个月,CO的治疗时间为6个月;在GH治疗的3、6、9和12个月(C和A)和3、6个月(CO)和停药后6个月(A和CO)之前和之后进行了调查。将从患者获得的数据与在两个年龄和性别匹配的对照组中记录的数据进行比较。治疗前,伴有GHD的C组血清PIIINP水平显着降低(p <0.001)(平均+/- SE:2.9 +/- 0.4 ng / ml),而对照组(6.1 +/- 0.4 ng / ml)没有显着降低记录了CO / A-GHD成人(3.7 +/- 0.5 ng / ml和3.4 +/- 0.2 ng / ml)与对照组(3.2 +/- 0.2 ng / ml)之间的差异。 GH治疗导致C的PIIINP水平显着增加(p <0.0001)(第3个月:4.4 +/- 0.2 ng / ml,第6个月:5.1 +/- 0.4 ng / ml,第12个月:5.1 +/- 0.5 ng / ml),CO-GHD(第三个月:12.7 +/- 1.2 ng / ml;第六个月:10.2 +/- 0.6 ng / ml)和A-GHD(第三个月:10.0 +/- 1.0 ng / ml;第6个月:8.4 +/- 0.6 ng / ml;第12个月:7.0 +/- 0.7 ng / ml),这种增加是剂量依赖性的(在患有CO-GHD的成年人中更为明显和持续)。 GHD成年人接受GH治疗3个月后,胶原蛋白合成受到最大刺激,而GHD的C则观察到逐渐增加和相关性降低。停止GH治疗6个月后,CO-GHD成人(3.6 +/- 0.3 ng / ml)的血清PIIINP水平与治疗前相似,而A-GHD成人P-NPNP水平(2.6 + / -0.2 ng / ml)显着低于基础状态(p <0.01)。总之,我们的研究表明:a)GHD与儿童软组织形成的减少有关,而对GHD成人似乎没有任何相关作用; b)生长激素疗法可迅速刺激胶原蛋白更新,在儿童和成人中表现出不同的模式; c)在停止GH治疗后,迅速消除了GH诱导的胶原蛋白合成的刺激。由于这些原因,确定GH作用的周围标志物似乎可用于监测GH治疗,并可有助于评估个体患者的“量身定制”替代剂量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号